Location History:
- Takasaki, JP (1998 - 2003)
- Gunma, JP (2004 - 2009)
Company Filing History:
8 out of 215 
1 out of 1,696 
1 out of 42 Years Active: 1998-2009
Title: Innovations of Yasuhiko Koezuka
Introduction
Yasuhiko Koezuka is a prominent inventor based in Takasaki, Japan. He has made significant contributions to the field of immunology, particularly in the development of adjuvants for vaccines. With a total of 10 patents to his name, Koezuka's work has the potential to impact the treatment of various infectious and neoplastic diseases.
Latest Patents
One of his latest patents focuses on the use of glycosylceramides as adjuvants for vaccines against infections and cancer. This invention relates to methods and compositions that augment the immunogenicity of an antigen in mammals. By administering an antigen alongside an adjuvant composition that includes glycosylceramide, particularly α-galactosylceramide (α-GalCer), the invention enhances antigen-specific Th1-type responses, especially CD8+ T cell responses. This method can be beneficial for both prophylaxis and treatment of various diseases.
Another notable patent involves a method for activating human antigen-presenting cells. This invention describes the in vitro cultivation of human-derived antigen-presenting cells with specific glycoside compounds. The activated cells can be used in the treatment of cancer and infectious diseases, including AIDS, providing a satisfactory therapeutic effect without the need for tumor antigens.
Career Highlights
Koezuka has worked with notable organizations such as Kirin Beer Company and New York University. His experience in these institutions has contributed to his innovative research and development in the field of immunology.
Collaborations
Some of his coworkers include Kazuhiro Motoki and Koji Kabaya. Their collaboration has likely played a role in advancing Koezuka's research and patent developments.
Conclusion
Yasuhiko Koezuka's contributions to immunology through his patents demonstrate his commitment to advancing medical science. His innovative approaches to vaccine adjuvants and human antigen-presenting cell activation hold promise for future therapeutic applications.